1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Spectrum Pharmaceuticals Announces Outstanding ZEVALIN … – Business Wire (press release)

June 18, 2012Monoclonal Anti-CD20 Antibodiesadmin

Proactive Investors USA & Canada

Spectrum Pharmaceuticals Announces Outstanding ZEVALIN ...
Business Wire (press release)
The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) ... Most (80%) fatalities occurred with the first rituximab infusion.
SPECTRUM PHARMACEUTICALS, INC. : Spectrum ...4-traders
New clinical data for ZEVALIN Injection for intravenous use ...News-Medical.net

all 15 news articles »

Post navigation

← Donating loved one's organs can bring solace amidst grief of loss, families say More Hospitalizations, Higher Charges, for Kids With High Blood Pressure →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos